In another study, a methylation panel of six genes (CDO1, HOXA9, AJAP1, PTGDR, UNCX, and MARCH11) in serum samples was revealed to correctly distinguish between stage IA NSCLC and control subjects with a sensitivity of 72.1% and a specificity 71.4%40. The gene discussed is MARCHF11; the disease is non-small cell lung carcinoma.